Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100774 | 0.79 | ABL1 (0.34) | ABL1 | |
| SCHEMBL23421555 | 0.79 | ACP1 (0.38) | ABL1PDE10AGCKKDM4EMAPK1 | |
| SCHEMBL21477606 | 0.75 | DHFR (0.32) | — | |
| SCHEMBL19386404 | 0.73 | GABRA1 (0.40) | ABL1PDE10AGABRA1GABRB2KDM4E | |
| SCHEMBL13238097 | 0.72 | CCR1 (0.47) | KDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL23432578 | 0.71 | ABL1 (0.34) | ABL1GABRA1POLBMAPK1 | |
| SCHEMBL18417280 | 0.70 | GABRA1 (0.40) | ABL1GABRA1GABRB2POLB | |
| SCHEMBL19513277 | 0.69 | GABRA1 (0.42) | ABL1PDE10AGABRA1GABRB2 | |
| SCHEMBL21037209 | 0.69 | PDE10A (0.36) | ABL1PDE10AGABRA1GABRB2 | |
| SCHEMBL21037108 | 0.69 | AKT1 (0.40) | ABL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | ABL1 542/4885PDE10A 970/4885GABRA1 639/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ABL1 542/4885PDE10A 970/4885GABRA1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.